ADAR1 Capital Management LLC boosted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 33.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 988,468 shares of the company's stock after buying an additional 245,834 shares during the period. ADAR1 Capital Management LLC owned approximately 0.58% of Savara worth $3,035,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock valued at $191,000 after acquiring an additional 3,706 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after purchasing an additional 4,732 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Savara by 5.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock valued at $533,000 after purchasing an additional 6,141 shares during the last quarter. SG Americas Securities LLC grew its position in Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock worth $158,000 after purchasing an additional 6,330 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Savara by 6.8% during the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock valued at $434,000 after buying an additional 9,041 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.
Savara Price Performance
Shares of NASDAQ:SVRA traded up $0.28 during midday trading on Friday, reaching $2.92. 594,311 shares of the company's stock traded hands, compared to its average volume of 1,336,003. The company has a fifty day simple moving average of $2.72 and a two-hundred day simple moving average of $3.13. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.33. The company has a market cap of $504.09 million, a P/E ratio of -6.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. Equities analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently commented on SVRA shares. JMP Securities restated a "market outperform" rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company assumed coverage on shares of Savara in a research note on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Savara in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.83.
Get Our Latest Research Report on SVRA
About Savara
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
